Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 3629206 | Hepatotoxicity associated with low-dose, long-term methotrexate treatment of rheumatoid ar | 1987 | Liver biopsies were performed in 17 patients with therapy-refractory rheumatoid arthritis who were treated successfully with 5-15 mg/week methotrexate (mtx). The average duration of exposure to mtx therapy for each patient was 2.8 years (range 1.5-5 years). Total cumulative mtx doses ranged between 633 and 1,655 mg (mean 1,060 mg). The biopsies revealed 16 cases of normal histology, of which 3 showed nuclear variability in the hepatocytes; 4 with mild fatty infiltration, 2 with mild fatty infiltration and portal round cell infiltration. Portal fibrosis was found in one patient who had psoriasis in addition to clinical RA. | |
| 3532404 | [Study of pirprofen (rengasil) combined with maintenance doses of corticosteroids in rheum | 1986 | A study of pirprofen (rengasil) combined with small doses of corticosteroids in 93 patients with rheumatoid arthritis during a double blind multicentre testing showed good and satisfactory therapeutic results in 60%. A decrease in morning rigidity, pains in the joints especially at night, the joint index and in the number of inflammed joints was noted. Rengasil tolerance was good, side effects were few. The new nonsteroid antiinflammatory drug rengasil combined with maintenance doses of corticosteroids can be recommended for a prolonged treatment of patients with rheumatoid arthritis. | |
| 2377861 | [A fluorescence spectrometric study of synovial exudate in the diagnosis of chronic joint | 1990 Jan | The spectro-fluorescent characteristics of synovial exudate in different diseases of the knee joint were studied. It was established that in pigmented villonodular synovitis the position of the maximum of fluorescence spectrum of synovial exudate was in the range of 510-530 nm and in synovitis of other etiology 430-440 nm. The authors propose a method of differential diagnosis of pigmented villonodular synovitis by fluorescent parameters of synovial exudate. | |
| 2812476 | [Basic treatment of rheumatoid arthritis with tiopronin. A study of 25 cases]. | 1989 Sep | In the basic treatment of 25 cases of classic or ARA defined rheumatoid arthritis, Tiopronin (alpha-mercaptopropionylglycine) was used for one year. The results obtained showed its therapeutic efficacy, as proven by the remission or improvement in humoral indexes of phlogosis and the suspension or dose reduction of steroid drugs and/or FANS in a high percentage of treated patients (84%). Nephrotic syndrome (1:25) and ageusia (1:25) were the most important side effects. These are common to the other sulfhydryl drugs and probably connected with a particular genetic predisposition in rheumatoid patients. | |
| 1920329 | Intraarticular progesterone inhibits 3H-dexamethasone binding to synovial cells from patie | 1991 Jul | Glucocorticoids are known to exert their antiinflammatory effects through an interaction with specific hormone receptors. Progesterone is able to bind to these glucocorticoid receptors exerting either agonistic or antagonistic actions. We have reported that a single intraarticular injection of progesterone exerts a local antiinflammatory action in patients with rheumatoid arthritis (RA), suggesting an agonistic effect of progesterone on local glucocorticoid receptors. To corroborate this possible mechanism of action, we investigated the binding of 3H-dexamethasone to local glucocorticoid receptors in synovial tissue from 3 patients with active RA, before and 14 days after a single intraarticular injection of progesterone. Both cytoplasmic and nuclear 3H-dexamethasone binding sites were observed within synoviocytes, macrophages, fibroblasts, lymphocytes and endothelial cells. Dry radioautograms of biopsied synovial tissue demonstrated a marked decrease of 3H-dexamethasone binding following progesterone treatment in all patients (p less than 0.001 for each comparison). Although the number of cases is not large enough to draw definitive conclusions, our data confirm the marked anti-inflammatory effect of intraarticular progesterone and support the hypothesis of an agonistic effect of progesterone (or its metabolites) on glucocorticoid receptors. | |
| 2552571 | Leukotriene b4 production by peripheral blood neutrophils in rheumatoid arthritis. | 1989 | Leukotriene B4 (LTB4) is an activator of white blood cells (WBC) and it has been suggested that its inhibition may be useful in rheumatoid arthritis (RA). Its production by peripheral WBC has not yet been investigated. We measured LTB4 production in 105 patients with RA and compared it with 59 matched controls. C-reactive protein (CRP) and ESR were measured in 90 patients and correlated with LTB4 values. Ten millilitres of blood were drawn. Separation was undertaken to obtain polymorphonuclear leukocytes (PMN) which were stimulated with calcium ionophore, and the supernatant was frozen for radioimmunoassay of LTB4. Results show that RA patients produce significantly higher levels of LTB4. It has been suggested that blockage of the cyclo-oxygenase enzyme by non-steroid anti-inflammatory drugs (NSAID) leads to increased production of LT via the lipoxygenase enzyme. Twenty-one patients not taking NSAID were compared with 84 on therapy. There was no significant difference. A linear regression was used to obtain Pearson's correlation coefficients. With LTB4 and CRP, r = 0.3 (p less than 0.003). With LTB4 and ESR, r = 0.25 (p less than 0.02). Low but significant correlations with CRP and ESR were obtained. | |
| 3151145 | HLA-alloantigen associations in Greek patients with Sjögren's syndrome. | 1988 Feb | The frequency of HLA-A, -B, and -DR alloantigens was studied in 46 patients with primary Sjögren's syndrome (pSS), 14 patients with secondary Sjögren's syndrome (sSS) and rheumatoid arthritis (RA), 26 classical RA patients without clinical or histologic evidence of Sjögren's syndrome (SS) and 172 normal controls. A statistically significant increase in the frequency of HLA-DR5 alloantigen was observed in the pSS patients, compared with the controls (P less than 0.007, corrected). No differences were detected between pSS patients with or without extraglandular manifestations, nor were any found between anti-Ro(SSA) positive and negative patients. The frequency of HLA-DR3 alloantigen (30%) was not significantly higher in our pSS population than in controls (25%), nor was that of -DR4 in the RA or the sSS patients. The results of the present study indicate that the 'SS susceptibility gene' in Greek patients is linked with the HLA-DR5 expression gene and they support the hypothesis that the fundamental pSS gene may belong to another locus. | |
| 1707461 | Expression of the interleukin 6 gene in rheumatoid synovial fibroblasts. | 1990 Dec | A number of fibroblastoid synovial cell lines have been established from rheumatoid joints. These cell lines were shown to express the interleukin 6 (IL-6) gene constitutively, and exposure of these cells to 5 ng/ml of recombinant human interleukin 1 beta (IL-1 beta) increased IL-6 gene expression. Other recombinant human lymphokines, namely interferon-gamma, tumor necrosis factor-alpha, and granulocyte-macrophage colony stimulating factor had no enhancing effect on IL-6 gene expression. Dexamethasone added to the cultures at 10(-7) M concentration suppressed the constitutive expression of the IL-6 gene. At a concentration of 10(-5) M, dexamethasone partially suppressed the IL-1 enhanced expression of IL-6. The IL-6 gene probe also hybridized to RNA from unfractionated synovial fluid cells, peripheral blood T cells and non-T cells but not Epstein-Barr virus transformed peripheral blood B cells of patients with rheumatoid arthritis. Our results suggest that in rheumatoid arthritis, synovial fibroblasts actively participate in joint inflammation by lymphokine production. The coexpression of both IL-1 and IL-6 by one synovial fibroblast line suggests a mechanism for the perpetuation of synovitis. | |
| 2348423 | Treatment of rheumatoid arthritis with higher dose intravenous methotrexate. | 1990 Apr | A pilot study evaluated intravenous methotrexate (MTX) (initial dose 40 mg/m2; final dose, 26 mg/m2), weekly for 12 weeks in 10 patients with rheumatoid arthritis who failed oral MTX. Statistically significant differences were noted for all the response variables examined: joint count (p = 0.0017), morning stiffness (p = 0.014), global assessment (patient, p = 0.0032, physician, p = 0.029), Arthritis Impact Measurement Scale (p = 0.0004), erythrocyte sedimentation rate (p = 0.012), grip strength (right p = 0.044, left p = 0.011). All 7 patients who completed the 12-week treatment period fulfilled the predetermined criteria for response. Intravenous MTX at these doses has potential efficacy in this patient group. | |
| 3704512 | [Pyrithioxin and rheumatoid polyarthritis]. | 1986 Jan | After reviewing the literature, the authors demonstrate that pyrithioxine is active in rheumatoid arthritis. The effectiveness is marked by a 50 per cent reduction in the articular index in 59.7 per cent of cases, a reduction in the duration of morning stiffness in 49 per cent of cases, a decreased erythrocyte sedimentation rate in 52.4 per cent of cases and a statistically significant decrease in the mean of these parameters in relation to the mean value at the beginning of treatment. The good results were considered to be those cases in which two of the three criteria (articular index, morning stiffness and erythrocyte sedimentation rate) were decreased by at least 50 per cent. Secondary escapes from treatment (13 per cent) and suspension of treatment for intolerance were considered to represent treatment failures. A good result was obtained in 42.7 per cent of cases. Side effects were observed in 40.1 per cent of cases and were responsible for suspension of treatment in 22.8 per cent of cases. Half of the side effects consisted of muco-cutaneous reactions which generally appeared early and were benign. Haematological, renal and gastrointestinal effects and aguestia occurred more rarely. However, a number of patients died as a result of agranulocytosis, hepatitis or extramembranous glomerulonephritis. | |
| 2567214 | Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from p | 1989 Jun | We examined the activities of peptidases in synovial fluid from patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Dipeptidyl peptidase IV (DPP IV) activity was lower in synovial fluid from patients with RA, in contrast to the increase of DPP II activity in synovial fluid, as compared with OA. The DPP II/DPP IV ratio for synovial fluid was significantly higher in patients with RA than in patients with OA. A significant correlation was observed between the DPP II/DPP IV ratio for synovial fluid from patients with RA and the amount of C-reactive protein reaction. These results may be useful in the diagnosis of joint effusion of unknown origin. | |
| 3423752 | Scintigraphy of rheumatoid peripheral joints. Reliability of visual assessment vs. compute | 1987 | 99mTc-methylene diphosphonate (99mTc-MDP) scintigraphy of peripheral joints was studied by visual evaluation (Visual Assessment) of the scintigrams and by a computerized region-of-interest (ROI) method without, or with a reference region (ROI method or Corrected ROI method). Sixteen rheumatoid patients and a total of 477 peripheral joints were studied and the results compared with clinical joint activity evaluated by joint palpation. The ROI method without a reference proved to be insensitive and hence unsuitable for clinical use. The results of Visual Assessment and the Corrected ROI method correlated well with each other and with clinical joint activity. The sensitivity of the methods in detecting a clinically inflamed finger joint was: ROI 6%, Corrected ROI 71% and Visual Assessment 75%. The corresponding figures for peripheral joints of the feet were as follows: 28%, 41% and 58%. We conclude that, for clinical use, Visual Assessment of the scintigram is adequate and the method of choice. | |
| 2310222 | Measurement of plasma concentrations of polymorphonuclear elastase-alpha 1 proteinase inhi | 1990 Jan | The plasma concentration of granulocyte elastase in complex with alpha 1 proteinase inhibitor was determined in 32 patients with rheumatoid arthritis and eight with seronegative spondarthritis complicated by peripheral joint synovitis. Most patients had concentrations of complex which were within the range of the control group when measured by an 'in-house' enzyme linked immunosorbent assay, though several of the patients with rheumatoid arthritis had raised concentrations. When the complexes were measured by a commercially available assay, however, much higher values were obtained for many of the patients with rheumatoid arthritis. Evidence is presented indicating that the commercially available assay may suffer seriously from interference by rheumatoid factor. The possibility is discussed that most patients with rheumatoid arthritis may have plasma concentrations of elastase-alpha 1 PI which are normal or only slightly raised, and that previously published reports using assay systems similar to that available commercially might also have produced falsely raised values for many individuals with rheumatoid arthritis. | |
| 3238322 | The diurnal variation of serum hyaluronan in health and disease. | 1988 Dec | The variation of the serum concentration of hyaluronan during the day and between days has been investigated. In a group of healthy volunteers, the mean hyaluronan level was very stable over time except for a moderate but significant elevation after rising from bed in the morning. Patients with rheumatoid arthritis showed markedly increased hyaluronan concentrations 0.5-2 h after leaving bed. Patients with primary biliary cirrhosis exhibited high and rather constant levels during the day. A reference group of hospitalized patients with other diseases did not show any diurnal variation. The best reproducibility in hyaluronan determinations is obtained if specimens are taken before the subjects rise from bed or a few hours later, i.e. after the morning elevation of serum hyaluronan has subsided. In rheumatoid arthritis valuable information can be obtained by repeated sampling during the morning hours. | |
| 3752951 | Evaluation of water soluble and lipid soluble sialic acid levels as tumor markers. | 1986 Jul | Serum sialic acid and lipid-soluble sialic acid was measured in 39 cancer patients, 16 patients with Crohns disease, 13 patients with rheumatoid arthritis, 28 patients with osteoarthritis, and 40 normal patients. Sialic acid was also determined in several patients who had undergone extensive chemotherapy or radiation. Elevations of sialic acid were observed in 33 of 39 cancer patients (sensitivity = 85%). No elevations were observed in the normals (specificity = 100%). However, 11 of 13 patients with rheumatoid arthritis and 9 of 16 patients with Crohns disease had elevated sialic acid. Patients undergoing extensive chemotherapy or radiation for two months prior to sialic acid measurement frequently had normal values even though tumor was present. Four patients, who were found to have cysts instead of cancer on biopsy or pathological examination, had normal sialic acid values. Three patients with active leukemia had elevated sialic acid, but three patients whose leukemia was in remission had normal sialic acid levels. Correlations were also found between sialic acid from an enzymatic total sialic acid and the Ehrlich sialic acid, and also between total sialic acid measured by the Ehrlich method and lipid soluble sialic acid. | |
| 2206695 | Osseous temporomandibular joint abnormalities in rheumatic disease. Computed tomography ve | 1990 Jul | Computed tomography (CT) of the temporomandibular joint (TMJ) was compared with hypocycloidal tomography in 30 joints of 15 adults with rheumatic disease. CT included 1.5 mm thick axial scans (at 1.0 mm intervals) with reformatted oblique sagittal and oblique coronal sections. Multisection (at 2.0 mm intervals) tomography included oblique sagittal and occasionally, oblique coronal sections. CT demonstrated bone abnormalities in 21 and tomography in 20 joints, indicating high agreement between the imaging modalities regarding number of abnormal TMJs. Bone structures were, however, better visualized by multiplanar CT due to superior contrast and spatial resolution particularly in the most lateral and medial parts of the joint, indicating superiority of CT for depicting subtle bony TMJ abnormalities in patients with rheumatic disease. | |
| 3819454 | Non-gonococcal infectious arthritis: a retrospective study. | 1987 Jan | In a retrospective study the outcome of non-gonococcal infectious arthritis was evaluated in 76 adult patients admitted to the Leiden University Hospital between 1970 and 1984. The mortality rate was 12%, and complete recovery was achieved in only 19 of the 76 patients (25%). Each of the following had a significantly unfavourable influence on the residual joint function: duration of infection more than 14 days, female sex, presence of rheumatoid arthritis, and presence of a joint prosthesis. | |
| 3318426 | Nabumetone: a single-center three-week comparison with placebo in the treatment of rheumat | 1987 Oct 30 | Forty-six patients with definite or classical rheumatoid arthritis were entered into a three-week, double-blind, randomized, parallel study of nabumetone, 1,000 mg at bedtime, compared with placebo. Fifteen nabumetone-treated and 12 placebo-treated patients were evaluated for efficacy variables including physician's opinion of rheumatoid arthritis activity, patient's opinion of rheumatoid arthritis activity, articular index, morning stiffness, 50-foot walking time, grip strength, and acetaminophen consumption. Between-group analysis of improvement over baseline was significantly (p less than 0.05) greater for nabumetone-treated patients for six of the seven variables. Nabumetone was significantly favored over placebo in three global evaluations and significantly more placebo-treated (75 percent) than nabumetone-treated (20 percent) patients withdrew from the study due to an unsatisfactory therapeutic response. Of the 38 patients receiving the study medication, 22 percent of nabumetone-treated and 5 percent of placebo-treated patients reported adverse experiences either related to treatment or for which the relationship to treatment was unknown. No patients were withdrawn from the study as a result of these experiences and no long-term sequelae or clinically significant laboratory abnormalities were reported. | |
| 3656314 | Association between azathioprine therapy and lymphoma in rheumatoid disease. | 1987 Jul | Three out of 41 patients treated with azathioprine and low-dose corticosteroids from 1976 to 1983 developed non-Hodgkin's lymphoma. This strikingly high incidence of lymphoma may be a reflection of long-term use of azathioprine. | |
| 3954467 | Cytidine deaminase activity as a measure of acute inflammation in rheumatoid arthritis. | 1986 Jan | Cytidine deaminase (CD), a cytoplasmic enzyme, is thought to leak out of damaged cells and can be measured in fluids by a simple biochemical assay. This study has shown that serum CD activity is raised in rheumatoid arthritis (RA) compared with osteoarthritis (OA). Synovial fluid (SF) CD activity was always less than the corresponding serum activity (mean SF/serum ratio = 0.6) in OA but up to 22 times greater than the corresponding serum activity in RA (mean SF/serum ratio = 13.1), suggesting CD production in inflammatory joints. Evidence to support the SF neutrophil as a cell of CD origin is provided by the CD gradient running from cells to SF to synovium. The close correlation between SF CD activity and neutrophil count (r = 0.93) indicates that SF CD activity is an accurate measure of acute synovial inflammation. Weak correlation of serum CD activity with erythrocyte sedimentation rate (ESR) (r = 0.44) and C-reactive protein (CRP) (r = 0.49) implies that CD estimations supply different though related information about rheumatoid disease activity. We suggest that CD released from damaged neutrophils diffuses from all inflamed joints into the blood, so that serum CD activity may provide an integrated measure of joint inflammation more specific than traditional measures such as the ESR. |